Fluorouracil and Palmar-Plantar Erythrodysesthesia
Authors: Charles F. Curran
Journal: Annals of Internal Medicine (1989)

Letters and Corrections15 November 1989Fluorouracil and Palmar-Plantar ErythrodysesthesiaCharles F. Curran, PhD., James K. Luce, MD.Charles F. Curran, PhD.Search for more papers by this author, James K. Luce, MD.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-10-858_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor:Nine cases of palmar-plantar erythrodysesthesia associated with fluorouracil have been reported to Adria Laboratories since 1981. The reactions described included tenderness, swelling, and erythema of palmar and plantar surfaces. Occasionally, the attendant pain was severe enough to interfere with walking and all hand-grasping activities. Varying degrees of desquamation occurred in three of the nine cases (33%). Only four patients (44%) received fluorouracil by continuous infusion for various intermittent periods, ranging from 15 to 59 consecutive days of dosing. All other patients received bolus doses. The duration of treatment before onset of the reaction ranged from 15 days...References1. Atkins J. Fluorouracil and the palmar-plantar erythrodysesthesia syndrome [Letter]. Ann Intern Med. 1985;102:419. LinkGoogle Scholar2. LokichMoore JC. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome [Letter]. Ann Intern Med. 1984;101:798-800. LinkGoogle Scholar3. FaintuchShepardO'LaughlinBeschornerGaynorLevin JKKJEB. Toxicity of continuous infusion 5-FU [Abstract]. Proc Am Soc Clin Oncol. 1985;4:92. Google Scholar4. MolinaFabianSlavikDahlberg RCMS. Reversal of palmar-plantar erythrodysesthesia (PPE) by B6 without loss of response in colon cancer patients receiving 200mg/m2/day continuous 5-FU [Abstract]. Proc Am Soc Clin Oncol. 1987;6:90. Google Scholar5. LokichAhlgrenGulloPhilipsFryer JJJJJ. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425-32. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Adria Laboratories Columbus, OH 43216. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySymptom Management in Gastrointestinal CancersFluorouracilDRUGS USED IN CANCER CHEMOTHERAPYPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centrePeripheral neuropathy exacerbation associated with topical 5-fluorouracilVascular Toxicity of Antineoplastic AgentsFluorouracilPalmoplantare Erythrodysästhesie nach intravenöser Therapie mit DocetaxelPalmar-plantar erythrodysesthesiaPalmar-Plantar Erythrodysaesthesia Associated with an Initial Course of Bolus FluorouracilThe clinical pharmacology of the oral fluoropyrimidinesCytostatic drugsMucocutaneous reactions to chemotherapyPalmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapy–An Underestimated Toxic Event?Axillary hyperpigmentation with 5-fluorouracil/cis-platinum combination therapyThree Cases of Chemotherapy-induced Acral ErythemaDermatological Toxicity from Chemotherapy Containing 5-FluorouracilChemotherapy-induced acral erythemaLocal Tissue Reaction to Intravenous Fluorouracil and Leucovorin 15 November 1989Volume 111, Issue 10Page: 858-858KeywordsDesquamationErythemaInflammationWalking Issue Published: 15 November 1989 PDF DownloadLoading ...